ArticleEndocrine2026
Clinical value of multi-time-point
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aimed to determine the suitable imaging time and validate the diagnostic accuracy of 68Ga-Pentixafor PET/CT for subtyping primary aldosteronism (PA).
methodsThis two-part study enrolled patients with PA. Part 1 identified suitable PET/CT time points (0–120 min) using multi-time-point imaging. Part 2 assessed the diagnostic performance in distinguishing unilateral PA (UPA) and bilateral PA (BPA). The diagnostic classification integrated AVS lateralization, imaging (visual analysis and lateralization index [LI] based on SUVmax and SUVpeak), and follow-up.
resultsThe multi-time-point group (n = 33) showed distinct SUVmax kinetics: the dominant adrenal glands in UPA patients peaked at 10 min (mean SUVmax, 18.27; sustained for 40 min), while the adrenal glands in BPA patients peaked at 5 min (9.6; sustained for 10 min). Normal adrenal glands peaked at 5 min (5.51). The SUVmax differed significantly between normal adrenal glands and both abnormal uptake patterns at all time-points (P < 0.05), while the SUVmax of dominant glands in UPA and glands in BPA began to differ significantly after 10 min post-injection (P < 0.05). In the subtype group (n = 101), 10-min LI based on SUVmax (cutoff 1.655) achieved 86.1% specificity, 89.1% accuracy, and an area under the curve of 0.943 (95% CI: 0.901–0.985). The 10-min visual analysis showed 93.8% sensitivity. Notably, diagnostic performance remained remarkably stable regardless of the quantification parameter used (LI-SUVmax vs. LI-SUVpeak), both yielding nearly identical accuracies (89.1% vs. 88.1% at 10 min). The 10-min LI based on SUVmax agreed with the AVS (83.8%) and surgical outcomes (87.9%), confirming its clinical utility.
conclusionEarly 10-min and late 40-min phases are suitable for 68Ga-Pentixafor PET/CT in PA. The 10-min LI and visual analysis demonstrate significant potential as non-invasive tools for PA subtyping. The LI is a remarkably robust and parameter-independent metric, providing high diagnostic consistency across different calculation methods and time points. Larger multicenter studies are needed to validate these findings.
Indexed as
Identifiers
42081148What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.